We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Procalcitonin Assay Will Help Determine Patients' Risk for Severe Sepsis

By HospiMedica staff writers
Posted on 12 Nov 2007
A procalcitonin assay (PCT) is to be developed to assist with the early diagnosis of patients at risk for progression to severe sepsis.

Sepsis with acute organ dysfunction (severe sepsis) is the main cause of death in non-coronary intensive care units. More...
In the United States, more than 750,000 patients develop severe sepsis each year. The number of cases of severe sepsis is increasing because of the emergence of drug-resistant microorganisms due to the widespread use of antibiotics. Despite an enormous investment in critical care resources, severe sepsis mortality ranges from 28-50%.

Siemens Medical Solutions Diagnostics (Tarrytown, NY USA) has signed an agreement with Brahms Aktiengesellschaft (Hennigsdorf, Germany) for the rights to develop, produce, and distribute the PCT test. Brahms Aktiengesellschaft will have the exclusive distribution rights in relevant European markets for the PCT test manufactured by Siemens Medical Solutions Diagnostics under the Brahms' license. Siemens will distribute the test to markets outside Europe. The PCT test has already received regulatory approvals in Japan and the United States. Outside Europe, the licensed PCT test will be available on both the Advia Centaur and Immulite immunoassay platforms from Siemens, whereas in Europe the licensed PCT test will only be available on the Advia Centaur platform.

"Early diagnosis and appropriate therapy of sepsis is a daily challenge in intensive care units,” said Joe Bernardo, senior vice president, Central Lab Testing, Siemens Medical Solutions Diagnostics. "This agreement highlights the enormous potential to help attending physicians recognize clinically relevant bacterial infections and estimate the risk of a septic complication, which can often have fatal consequences. Our goal is to focus on new opportunities to provide the diagnostic tools necessary to diagnose and treat millions of patients. This collaboration demonstrates our commitment to that goal.”

"The co-operation with Siemens Medical Solutions Diagnostics for now completes our strategic alliances on Procalcitonin aimed to allow diagnostic laboratories all over the world the access to one of the clinically most relevant biomarkers,” stated Herbert Sucka, chief marketing officer of Brahms.


Related Links:
Siemens Medical Solutions Diagnostics
Brahms Aktiengesellschaft

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.